Healthy Clinical Trial
Official title:
Randomized-controlled Trial to Assess the Effects of Different Trans-fatty Acids on Endothelial Function in Humans
Verified date | July 2013 |
Source | University Hospital Inselspital, Berne |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Interventional |
The aim of the study is to compare a diet rich in trans fatty acids (TFA) from ruminant
sources with a diet rich in TFA from hydrogenated vegetable oils (PHVO) in regard to their
effects on cardiovascular risk markers (endothelial function, blood lipids, inflammation and
coagulation parameters in the blood).
After a two week run-in period (diet without TFA) volunteers are randomized into three
groups with different diets: diet rich in TFA from ruminant sources, diet rich in TFA from
PHVO and diet without TFA. The intervention period lasts four weeks.
A nutritionist introduces the basic issues of the study diets. All volunteers supply
themselves according to the recommendations of the Swiss food pyramid. Fat free food can be
chosen individually in the context of defined guidelines. The amount and source of the fat
in the diet are strictly defined. During the whole study, volunteers meet the nutritionist
every 2 weeks, and in the weeks between, the volunteers are contacted by phone.
The volunteers will continue their normal daily life and physical activities. At the
beginning of the run-in period and at the beginning and the end of the intervention period
the endothelial function of the brachial artery will be assessed using flow-mediated
dilation (FMD)/nitro-mediated dilation (NMD) methods and blood samples will be collected to
analyze blood lipids, inflammation and coagulation parameters in the blood.
Hypothesis:
1. Diet enriched with ruminant TFA has not the same negative effect on cardiovascular risk
markers as diet enriched with the same amount of industrial TFA compared with a diet
without TFA.
2. Diet enriched with ruminant TFA has not a more negative effect on cardiovascular risk
markers as diet without TFA.
Status | Terminated |
Enrollment | 142 |
Est. completion date | June 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 45 Years to 69 Years |
Eligibility |
Inclusion Criteria: - age 45-69 - body mass index 20-30 kg/m2 - willingness to hold physical activity constant over study duration - written informed consent Exclusion Criteria - smoking - hypertension (> 140/90 mm Hg) - hypotension (men < 115 mm Hg; women < 105 mm Hg) - obesity (BMI =/> 30 kg/m2) - vegan - infections in the last 6 weeks - allergy for food (e.g., milk) - pregnancy - diabetes (elevated fasting blood glucose level) - clinical known coronary diseases - acute and/or chronical medication (incl. contraceptive) - abnormal kidney function - abnormal liver function - known cardiac arrhythmia (e.g., atrial fibrillation) - blood parameters (ALAT, Creatinin, Hb, potassium, CRP) in range |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Switzerland | Cardiovascular Prevention and Rehabilitation, Bern University Hospital | Bern |
Lead Sponsor | Collaborator |
---|---|
University Hospital Inselspital, Berne | Agroscope Liebefeld-Posieux Research Station ALP, Bundesamt für Landwirtschaft, Emmi Schweiz AG, Schweizerische Herzstiftung, University of Bern |
Switzerland,
Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willett WC. Trans fatty acids and coronary heart disease. N Engl J Med. 1999 Jun 24;340(25):1994-8. — View Citation
Chardigny JM, Destaillats F, Malpuech-Brugère C, Moulin J, Bauman DE, Lock AL, Barbano DM, Mensink RP, Bezelgues JB, Chaumont P, Combe N, Cristiani I, Joffre F, German JB, Dionisi F, Boirie Y, Sébédio JL. Do trans fatty acids from industrially produced so — View Citation
Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest. 2005 Jun;127(6):2254-63. Review. — View Citation
Motard-Bélanger A, Charest A, Grenier G, Paquin P, Chouinard Y, Lemieux S, Couture P, Lamarche B. Study of the effect of trans fatty acids from ruminants on blood lipids and other risk factors for cardiovascular disease. Am J Clin Nutr. 2008 Mar;87(3):593 — View Citation
Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr. 2009 May;63 Suppl 2:S5-21. doi: 10.1038/sj.ejcn.1602973. Review. — View Citation
Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006 Apr 13;354(15):1601-13. Review. — View Citation
Willett WC, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Rosner BA, Sampson LA, Hennekens CH. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet. 1993 Mar 6;341(8845):581-5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | endothelial function using flow-mediated dilation | 3 time points over 6 weeks (after 0, 2, 6 weeks) | No | |
Secondary | inflammation parameters in blood samples | 6 weeks | No | |
Secondary | coagulation parameters in blood samples | 6 weeks | No | |
Secondary | blood lipids in blood samples | 6 weeks | No | |
Secondary | adhesion molecules in blood samples | 6 weeks | No | |
Secondary | insulin resistance via blood samples | 6 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |